title: Topoisomerase II as a target of antileukemic drugs.
abstract: The identification of topoisomerase II as a target of antineoplastic drug therapy is traced from the original observations by Ross et al. (1,2) in murine leukemia cells through studies with m-AMSA-resistant human leukemia cells. Recently developed quantitative biochemical assays of topoisomerase II activity and the susceptibility of topoisomerase II to the effects of m-AMSA have allowed the principles identified in murine and human leukemia cell culture systems to be applied to clinical material; a prospective trial is testing the utility of such assays for individualizing antineoplastic drug therapy.
authors.forename: L A
authors.initials: LA
authors.lastname: Zwelling
authors.forename: E
authors.initials: E
authors.lastname: Estey
authors.forename: M
authors.initials: M
authors.lastname: Bakic
authors.forename: L
authors.initials: L
authors.lastname: Silberman
authors.forename: D
authors.initials: D
authors.lastname: Chan
mesh_terms: D000677:Amsacrine / Q000627:therapeutic use*; D000818:Animals; D004250:DNA Topoisomerases, Type II / Q000378:metabolism*; D004351:Drug Resistance; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000201:enzymology; D007942:Leukemia, Experimental / Q000188:drug therapy* / Q000201:enzymology; D051379:Mice
chemical_list: D000677:Amsacrine; D004250:DNA Topoisomerases, Type II